FCRL1 and diffuse large B-cell lymphoma: The current research aimed to investigate whether FCRL1 or BAFF is a suitable target for diagnosing, prognosticating, and improving therapeutic outcomes in Egyptian DLBCL, the most common type of B-NHL, patients treated with R-CHOP.